HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 32.65
-0.18 (-0.55%)
At close: Jan 22, 2026
HitGen Revenue
HitGen had revenue of 142.78M CNY in the quarter ending September 30, 2025, with 37.89% growth. This brings the company's revenue in the last twelve months to 498.51M, up 17.61% year-over-year. In the year 2024, HitGen had annual revenue of 426.99M with 14.99% growth.
Revenue (ttm)
498.51M
Revenue Growth
+17.61%
P/S Ratio
26.31
Revenue / Employee
1.03M
Employees
483
Market Cap
13.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 426.99M | 55.66M | 14.99% |
| Dec 31, 2023 | 371.32M | 41.67M | 12.64% |
| Dec 31, 2022 | 329.65M | 18.59M | 5.98% |
| Dec 31, 2021 | 311.06M | 67.46M | 27.69% |
| Dec 31, 2020 | 243.60M | -20.60M | -7.80% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |